HomeDCTH • NASDAQ
add
Delcath Systems Inc
Previous close
$6.96
Day range
$7.00 - $7.71
Year range
$2.25 - $7.99
Market cap
210.33M USD
Avg Volume
281.05K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 539.00K | -15.65% |
Operating expense | 11.67M | 41.36% |
Net income | -11.14M | -31.44% |
Net profit margin | -2.07K | -55.83% |
Earnings per share | -0.48 | 44.19% |
EBITDA | -11.26M | -44.01% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 32.45M | 323.07% |
Total assets | 38.61M | 116.17% |
Total liabilities | 17.29M | -27.12% |
Total equity | 21.32M | — |
Shares outstanding | 24.56M | — |
Price to book | 10.09 | — |
Return on assets | -65.58% | — |
Return on capital | -78.39% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -11.14M | -31.44% |
Cash from operations | -8.18M | -11.13% |
Cash from investing | -19.67M | — |
Cash from financing | 1.00K | -99.98% |
Net change in cash | -27.82M | -1,187.78% |
Free cash flow | -3.64M | 10.31% |
About
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
Founded
1988
Headquarters
Website
Employees
76